No Data
No Data
Express News | Foghorn Therapeutics Says Flagship Pioneering Raised $3.6B To To Support The Creation And Development Of An Estimated 25 Breakthrough Companies In Human Health
Flagship Pioneering Raises $3.6 Billion to Fuel Breakthrough Innovations That Transform Human Health and Sustainability
Flagship Pioneering, the bioplatform innovation company, today announced it has expanded its capital base by $3.6 billion to support the creation and ...
Flagship Pioneering Expands Leadership Team With Key Appointments and Promotions
Flagship Pioneering, the bioplatform innovation company, today announced additions to its leadership team through key executive appointments and...
Flagship Pioneering and ProFound Therapeutics Announce Agreement to Identify Novel First-in-Class Therapeutics for the Treatment of Obesity Under Strategic Partnership With Pfizer
Flagship Pioneering and ProFound Therapeutics, a Flagship-founded company pioneering the expanded human proteome to develop novel medicines for a...
Foghorn Therapeutics to Participate in Upcoming Investor Conferences in June
CAMBRIDGE, Mass., May 28, 2024 (GLOBE NEWSWIRE) -- Foghorn Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by
Foghorn Therapeutics Raises ~$110 Million Through Direct Offering
No Data